STOCK TITAN

FOXO Technologies Inc. - FOXO STOCK NEWS

Welcome to our dedicated page for FOXO Technologies news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO Technologies stock.

FOXO Technologies Inc. (symbol: FOXO) is leading the charge in transforming the global longevity and life insurance industries through cutting-edge epigenetic technology and AI-driven solutions. Founded under the names Yousurance and Life Epigenetics, the company has redefined how we understand and measure health and aging.

FOXO’s core business revolves around commercializing longevity science by utilizing epigenetic biomarkers to assess the biological age and health status of individuals. This revolutionary approach not only impacts life insurance underwriting protocols but also engages consumers directly through an advanced platform.

With a focus on DNA methylation, FOXO leverages supervised machine learning and artificial intelligence to pinpoint molecular signs of aging and health conditions. This enables more accurate risk assessment and personalized health insights, setting new standards in the insurance sector.

Recent achievements include groundbreaking advancements in epigenetic research and the integration of AI to enhance the precision of health evaluations. The company's current projects aim to further refine these technologies and expand their application range, ensuring they remain at the forefront of innovation in their field.

Financially, FOXO Technologies Inc. is committed to sustained growth and solidifying its market presence through strategic partnerships and continual investment in research and development. Their collaborations with leading scientific institutions and industry partners underscore their commitment to excellence and innovation.

Stay updated with the latest news and developments to see how FOXO Technologies Inc. continues to shape the future of longevity and health insurance.

Rhea-AI Summary

FOXO Technologies Inc. (NYSEAM: FOXO) has filed its Form 10-Q for the third quarter ended September 30, 2022, after initially delaying it to review the accounting treatment of certain warrants and Series A Preferred Stock. The company confirmed that the accounting treatment was appropriate. Despite macro challenges, FOXO launched its first Longevity Report and an automated epigenetic testing system while integrating with two partners. The interim CEO expressed confidence in the company's direction, emphasizing innovation and adaptability to enhance user experience. FOXO has postponed its Q3 earnings call, planning instead for a Q4 update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none
-
Rhea-AI Summary

FOXO Technologies Inc. has announced significant changes in its executive leadership as of November 14, 2022. Jon Sabes has been terminated as CEO and Chairman of the Board. Tyler Danielson, previously Chief Technology Officer, has been appointed Interim CEO, while Bret Barnes takes over as Chairman. The company is in the process of searching for a permanent CEO. Additionally, Steve Sabes has been terminated as COO. FOXO plans to file for an extension with the SEC for its quarterly report for the period ending September 30, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.74%
Tags
management
-
Rhea-AI Summary

FOXO Technologies Inc. (AMEX: FOXO) announced the resignation of Chief Product Officer Erin Sharoni effective November 9, 2022. The company expressed gratitude for her leadership, particularly regarding the FOXO Longevity Report. FOXO Technologies focuses on applying epigenetic science and AI to modernize the life insurance sector through innovative products and services aimed at improving underwriting processes and consumer value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.74%
Tags
none
Rhea-AI Summary

FOXO Technologies Inc. (AMEX: FOXO) has announced the postponement of its earnings conference call, with a subsequent press release to reveal the new date and time. This delay could indicate potential issues or uncertainty regarding the company's financial performance and outlook. FOXO operates at the intersection of technology and life insurance, focusing on epigenetic longevity science aimed at improving consumer underwriting processes through innovations like the FOXO Longevity Report™.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.74%
Tags
-
Rhea-AI Summary

FOXO Technologies has announced a new managing general agency agreement between its subsidiary, FOXO LIFE, and Haven Life, a subsidiary of MassMutual. This strategic partnership aims to enhance FOXO LIFE's distribution of Haven Life insurance products through independent agents. This collaboration is set to expand FOXO LIFE's market reach, leveraging Haven Life's innovative digital purchasing experience in the life insurance sector. The announcement comes ahead of the NAILBA Annual Meeting, emphasizing FOXO's commitment to modernizing life insurance through technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
none
-
Rhea-AI Summary

FOXO Technologies Inc. (FOXO) announced it will report its financial results for the third quarter of 2022 on November 14, 2022, after market close. A conference call will be held at 3:15 p.m. Central time on the same day to discuss the results and recent business highlights. FOXO is focused on leveraging epigenetic technology to modernize the life insurance industry, utilizing AI to analyze DNA methylation for health biomarkers, enhancing the underwriting process, and improving consumer value prop through its FOXO Longevity Report.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
Rhea-AI Summary

FOXO Technologies Inc. (AMEX: FOXO) announced the recruitment of its first distribution partner, BGA Insurance, which represents over 4,000 independent agents in California. This partnership aims to promote longevity-focused life insurance products through FOXO LIFE. Additionally, James Grauel, Jr. has been appointed as Chief Distribution Officer to lead these efforts. The company will conduct agent recruitment events in Southern California starting October 19, 2022. The announcement follows FOXO's recent public trading debut with an enterprise value of approximately $369 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
59.24%
Tags
none
-
Rhea-AI Summary

FOXO Technologies Inc. announced the completion of its business combination with Delwinds Insurance Acquisition Corp., with trading starting on the NYSE American under the symbol 'FOXO' from September 16, 2022. This strategic move aims to address key issues within the life insurance sector through epigenetic longevity science. FOXO's inaugural Managing General Agency relationship allows for marketing a range of life insurance products bundled with the FOXO Longevity Report™. The business combination received over 91% shareholder approval, underscoring strong investor confidence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of FOXO Technologies (FOXO)?

The current stock price of FOXO Technologies (FOXO) is $0.139 as of November 4, 2024.

What is the market cap of FOXO Technologies (FOXO)?

The market cap of FOXO Technologies (FOXO) is approximately 1.9M.

What does FOXO Technologies Inc. specialize in?

FOXO Technologies Inc. specializes in applying epigenetic technology and AI to transform the life insurance industry through advanced risk assessment and consumer engagement.

How does FOXO's technology work?

FOXO uses DNA methylation and AI to identify molecular biomarkers that reveal insights into an individual's health and aging, allowing for more accurate underwriting in life insurance.

What are epigenetic biomarkers?

Epigenetic biomarkers are molecular signs found in DNA that indicate current health status and biological age, which FOXO utilizes to enhance life insurance underwriting.

How is FOXO Technologies Inc. impacting the life insurance industry?

By employing epigenetic technology and AI, FOXO is revolutionizing life insurance underwriting, making it more precise and personalized.

What are some recent achievements of FOXO Technologies Inc.?

Recent milestones include advancements in epigenetic research, development of AI-driven health assessments, and strategic partnerships to enhance their technology platform.

What is FOXO Technologies Inc.’s approach to consumer engagement?

FOXO engages consumers through a platform that provides personalized health insights based on epigenetic biomarkers, enhancing their understanding of personal health and longevity.

Who are FOXO Technologies Inc.'s partners?

FOXO collaborates with leading scientific institutions and industry partners to advance their research and technology applications in the life insurance sector.

What is DNA methylation?

DNA methylation is a biological process where methyl groups are added to DNA, affecting gene expression without altering the DNA sequence. FOXO uses this process to identify health biomarkers.

Where is FOXO Technologies Inc. headquartered?

FOXO Technologies Inc. is headquartered in Minneapolis, as indicated in their latest news release.

What is the future outlook for FOXO Technologies Inc.?

FOXO is focused on continued innovation in epigenetic technology and AI, aiming for sustained growth and expanded applications in the life insurance industry.

FOXO Technologies Inc.

NYSE:FOXO

FOXO Rankings

FOXO Stock Data

1.85M
13.63M
18.79%
2.27%
0.36%
Health Information Services
Services-commercial Physical & Biological Research
Link
United States of America
MINNEAPOLIS